Ingalls & Snyder LLC bought a new position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,364 shares of the biopharmaceutical company’s stock, valued at approximately $881,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Valeo Financial Advisors LLC purchased a new position in Alexion Pharmaceuticals in the third quarter valued at about $147,000. Dupont Capital Management Corp acquired a new stake in Alexion Pharmaceuticals during the third quarter worth approximately $156,000. BT Investment Management Ltd acquired a new stake in Alexion Pharmaceuticals during the third quarter worth approximately $165,000. YorkBridge Wealth Partners LLC boosted its holdings in shares of Alexion Pharmaceuticals by 221.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock valued at $173,000 after buying an additional 982 shares during the period. Finally, Beacon Investment Advisory Services Inc. acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at about $201,000. 94.01% of the stock is owned by hedge funds and other institutional investors.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up $6.83 during trading on Monday, hitting $115.43. 2,659,627 shares of the company were exchanged, compared to its average volume of 2,020,000. The firm has a market cap of $25,790.00, a PE ratio of 58.59, a P/E/G ratio of 0.95 and a beta of 1.16. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 EPS. equities analysts predict that Alexion Pharmaceuticals, Inc. will post 6.25 EPS for the current year.
A number of research analysts have issued reports on the stock. Evercore ISI raised shares of Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research note on Monday, February 5th. SunTrust Banks set a $172.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Monday. Citigroup dropped their target price on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating on the stock in a report on Friday. Leerink Swann cut their price target on shares of Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a report on Friday. Finally, BMO Capital Markets boosted their price target on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a report on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty-one have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $152.77.
In other news, EVP John B. Moriarty sold 3,363 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $115.70, for a total value of $389,099.10. Following the transaction, the executive vice president now owns 71,400 shares of the company’s stock, valued at approximately $8,260,980. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Heidi L. Wagner sold 655 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30. Following the completion of the sale, the senior vice president now owns 32,635 shares in the company, valued at $3,826,780.10. The disclosure for this sale can be found here. Insiders sold a total of 28,930 shares of company stock worth $3,378,199 in the last ninety days. Insiders own 4.35% of the company’s stock.
WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/12/ingalls-snyder-llc-invests-881000-in-alexion-pharmaceuticals-inc-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.